This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Friday's Health Winners & Losers

Medical-equipment maker Urologix (ULGX) named a new chief financial officer.

Effective Friday, Elissa J. Lindsoe will head all treasury, investor relations, human resources, customer service, order management and information technology functions, the company said in a press release. Shares rose 4 cents to $2.84.

Biogen Idec (BIIB - Get Report) and Elan (ELN) presented new data this week showing that Tysabri improved the cognitive function of multiple sclerosis patients and had a sustained effect on relapse rates.

A study of the drug's long-term effects estimated that patients on Tysabri would have an average of one relapse every 4.3 years. Separately, according to new data from the Affirm trial presented Thursday, treatment with Tysabri alone significantly reduced the number of MS patients experiencing worsening scores on certain tests measuring their cognitive abilities.

Biogen Idec's shares were down 10 cents, or 0.2%, at $44.64. Elan slipped 6 cents, or 0.4%, to $15.42.

European regulators cleared an antismoking pill made by drug giant Pfizer (PFE - Get Report) about four months after it was given the green light in the U.S.

The approval of the drug, called Champix in Europe, was based on clinical trials involving 4,000 smokers who smoked an average of 21 cigarettes a day for an average of 25 years. Champix was approved by the Food and Drug Administration for smoking cessation in May under the brand name Chantix. Pfizer was up 20 cents to $28.50.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ELN $0.00 0.00%
AMGN $158.99 0.00%
BIIB $273.69 0.00%
CORT $5.05 0.00%
LLY $76.75 0.00%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs